News | May 04, 2024
Ajanta Pharma posts Q4 FY24 consolidated PAT at Rs. 202.72 Cr
The company has reported total income of Rs. 1,089.58 crores during the period ended March 31, 2024
The company has reported total income of Rs. 1,089.58 crores during the period ended March 31, 2024
The company has posted net profit of Rs.87.66 crores for the Financial Year ended March 31, 2024
Laurus Labs has reported total income of Rs. 1,458.20 crores during the period ended March 31, 2024
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
